Insurance firm Aviva has co-led a round for Owlstone Medical, whose roots can be traced back to University of Cambridge.
Owlstone Medical, UK-based respiratory disease diagnostics developer, has secured $15m in a funding round co-led by Aviva Ventures, the corporate venturing arm of insurance firm Aviva.
The round was co-led by venture capital firm Horizons Ventures and follows an investment of undisclosed size by Aviva in March 2017.
Owlstone Medical was spun out from Owlstone, itself a chemical detection technology spinout of University of Cambridge, in 2016.
The company is developing an early disease diagnosis breathalyser called Breath Biopsy that…
